close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Stay in touch with the latest information on SYNVISC

Subscribe to our email list and we will send you new information on a regular basis.

Physician Q & A

Why do leading physicians recommend SYNVISC® to their patients who have osteoarthritis (OA) of the knee? To find out, the Genzyme OA Leadership Forum interviewed prominent orthopedic surgeons and sports medicine experts who prescribe SYNVISC to their patients with OA of the knee.

Dr. David W. Waddell, MD | Dr. Nicholas DiNubile, MD | Dr. Clarence L. Shields, Jr. MD


Dr. David W. Waddell, MD

“…the more favorable dosing schedule of SYNVISC, combined with its magnitude of pain relief and tolerability profile, makes it my viscosupplement of choice.”

Leadership Forum (LF): Over 12,000 SYNVISC injections—that’s a significant number. How has viscosupplementation changed the way you treat OA knee pain?

David Waddell (DW): It’s given me an effective and well-tolerated option for those patients who have failed on other conservative treatments. I have a knee-only practice, so I see a lot of patients who have already run the range of nonpharmacologic and oral therapies for knee OA, including physical therapy, analgesics, and NSAIDs. For these patients, viscosupplementation has become one of my primary treatment considerations.

I also see a significant portion of patients, referred to my practice by other physicians, who might otherwise be candidates for knee replacement. Viscosupplementation is a viable alternative for those patients who would like to avoid, or at least delay, surgery.

The OA Leadership Forum is a service of Genzyme Corporation.
Dr. Waddell is a paid consultant of the Genzyme Corporation.


download PDF

Return to top



Dr. Nicholas DiNubile, MD

“Compared to prior generations, a significantly larger proportion of the boomer generation are participating in sports and fitness activities, putting added strain on aging knees.”

Leadership Forum (LF): You’ve spoken many times on the dramatic increase in the incidence of knee osteoarthritis (OA) among baby boomers. To what do you attribute this increase?

Nicholas DiNubile (ND): Based on the kind of middle-aged patients who present with knee OA in my practice, I think the reason for this “boomeritis” is twofold. First, a lot more of these people are staying active later—compared to prior generations, a significantly larger proportion of the boomer generation are participating in sports and fitness activities, putting added strain on aging knees. At the other end of the spectrum, a key risk factor for knee OA is obesity. Ironic, isn’t it?

The OA Leadership Forum is a service of Genzyme Corporation.
Dr. Shields is a paid consultant of the Genzyme Corporation.


download PDF

Return to top



Dr. Clarence L. Shields, Jr. MD

"Before considering viscosupplementation, I look to the modifiable factors, such as changing activities, decreasing body weight, and increasing strength…"

Leadership Forum (LF): Where does viscosupplementation fit in the treatment spectrum for your patients with mild to moderate knee osteoarthritis (OA)?

Clarence Shields (CS): Before considering viscosupplementation, I look to the modifiable factors, such as changing activities, decreasing body weight, and increasing strength, which improves the shock-absorbing ability of the knee joint. These steps give many patients a certain level of symptom relief. Next, I would probably start them on anti-inflammatory medication along with physical therapy. If after a couple of months those steps prove to be insufficient, or if I’d like to provide patients with a greater magnitude of relief, I might recommend viscosupplementation.

The OA Leadership Forum is a service of Genzyme Corporation.
Dr. Shields is a paid consultant of the Genzyme Corporation.


download PDF

Return to top




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)